HPV-based Tests for Cervical Cancer Screening and Management of Cervical Disease

Overview

Journal Curr Obstet Gynecol Rep

Specialty Gynecology & Obstetrics

Date 2013 May 25

PMID 23705102

Citations 6

Authors

Patricia Luhn

Nicolas Wentzensen

Affiliations

Soon will be listed here.

Abstract

Current cervical cancer screening programs are changing due to the development of tests that detect the presence of human papillomavirus (HPV), the cause of cervical cancer. These tests are more sensitive than cytology-based methods for detecting cervical precancer and a negative test offers long-term assurance that cervical cancer will not develop and therefore longer screening intervals can be achieved. In screening programs, HPV-based tests have been approved to triage women with equivocal cytology results and as a primary testing method in conjunction with cytology. HPV-based tests also have a role in determining risk of recurrence after treatment for cervical precancer as well as in surveillance for vaccine-related changes in HPV genotype prevalence.

Citing Articles

Expression of the IGF‑1Ea isoform in human placentas from third trimester normal and idiopathic intrauterine growth restriction singleton pregnancies: Correlations with clinical and histopathological parameters.

Fasoulopoulos A, Varras M, Varra F, Philippou A, Myoteri D, Varra V Mol Med Rep. 2025; 31(3.

PMID: 39791214 PMC: 11751665. DOI: 10.3892/mmr.2025.13434.

Human Papillomaviruses-Associated Cancers: An Update of Current Knowledge.

Pesut E, dukic A, Lulic L, Skelin J, Simic I, Milutin Gasperov N Viruses. 2021; 13(11).

PMID: 34835040 PMC: 8623401. DOI: 10.3390/v13112234.

Loop-Mediated Isothermal Amplification Assay for Detecting Tumor Markers and Human Papillomavirus: Accuracy and Supplemental Diagnostic Value to Endovaginal MRI in Cervical Cancer.

Wormald B, Rodriguez-Manzano J, Moser N, Pennisi I, Ind T, Vroobel K Front Oncol. 2021; 11:747614.

PMID: 34790573 PMC: 8591099. DOI: 10.3389/fonc.2021.747614.

Comparison of methods using paraffin-embedded tissues and exfoliated cervical cells to evaluate human papillomavirus genotype attribution.

Torii Y, Fujii T, Kukimoto I, Saito M, Iwata T, Takahashi H Cancer Sci. 2016; 107(10):1520-1526.

PMID: 27501394 PMC: 5084667. DOI: 10.1111/cas.13030.

Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods.

Castro F, Koshiol J, Quint W, Wheeler C, Gillison M, Vaughan L BMC Infect Dis. 2015; 15:544.

PMID: 26607224 PMC: 4660657. DOI: 10.1186/s12879-015-1281-5.

References

Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Hansson B . HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer. 2007; 97(1):129-32. PMC: 2359659. DOI: 10.1038/sj.bjc.6603843. View

Kreimer A, Guido R, Solomon D, Schiffman M, Wacholder S, Jeronimo J . Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev. 2006; 15(5):908-14. DOI: 10.1158/1055-9965.EPI-05-0845. View

Kitchener H, Almonte M, Gilham C, Dowie R, Stoykova B, Sargent A . ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess. 2009; 13(51):1-150, iii-iv. DOI: 10.3310/hta13510. View

Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand M . Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008; 26 Suppl 10:K29-41. DOI: 10.1016/j.vaccine.2008.06.019. View

Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage J, Castle P . Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011; 103(5):368-83. PMC: 3046952. DOI: 10.1093/jnci/djq562. View

Mayrand M, Duarte-Franco E, Rodrigues I, Walter S, Hanley J, Ferenczy A . Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007; 357(16):1579-88. DOI: 10.1056/NEJMoa071430. View

Kjaer S, Frederiksen K, Munk C, Iftner T . Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010; 102(19):1478-88. PMC: 2950170. DOI: 10.1093/jnci/djq356. View

Rodriguez A, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle P . Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008; 100(7):513-7. PMC: 3705579. DOI: 10.1093/jnci/djn044. View

Gage J, Ajenifuja K, Wentzensen N, Adepiti A, Eklund C, Reilly M . The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: implications for screen-and-treat strategies. Int J Cancer. 2011; 130(9):2111-7. PMC: 3227742. DOI: 10.1002/ijc.26211. View

10.

Cuzick J, Clavel C, Petry K, Meijer C, Hoyer H, Ratnam S . Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006; 119(5):1095-101. DOI: 10.1002/ijc.21955. View

11.

Wheeler C, Hunt W, Joste N, Key C, Quint W, Castle P . Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst. 2009; 101(7):475-87. PMC: 2664090. DOI: 10.1093/jnci/djn510. View

12.

Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C . Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol. 2009; 45 Suppl 1:S55-61. DOI: 10.1016/S1386-6532(09)70009-5. View

13.

Katki H, Kinney W, Fetterman B, Lorey T, Poitras N, Cheung L . Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011; 12(7):663-72. PMC: 3272857. DOI: 10.1016/S1470-2045(11)70145-0. View

14.

Clad A, Reuschenbach M, Weinschenk J, Grote R, Rahmsdorf J, Freudenberg N . Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology. J Clin Microbiol. 2010; 49(3):1071-6. PMC: 3067681. DOI: 10.1128/JCM.01674-10. View

15.

Burger E, Kornor H, Klemp M, Lauvrak V, Kristiansen I . HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol Oncol. 2010; 120(3):430-8. DOI: 10.1016/j.ygyno.2010.11.013. View

16.

Mirabello L, Sun C, Ghosh A, Rodriguez A, Schiffman M, Wentzensen N . Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J Natl Cancer Inst. 2012; 104(7):556-65. PMC: 3317880. DOI: 10.1093/jnci/djs135. View

17.

Belinson J, Wu R, Belinson S, Qu X, Yang B, Du H . A population-based clinical trial comparing endocervical high-risk HPV testing using hybrid capture 2 and Cervista from the SHENCCAST II Study. Am J Clin Pathol. 2011; 135(5):790-5. DOI: 10.1309/AJCPKA6ATAPBZ6JQ. View

18.

Cuzick J, Bergeron C, von Knebel Doeberitz M, Gravitt P, Jeronimo J, Lorincz A . New technologies and procedures for cervical cancer screening. Vaccine. 2012; 30 Suppl 5:F107-16. DOI: 10.1016/j.vaccine.2012.05.088. View

19.

Cox J . History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results. J Clin Virol. 2009; 45 Suppl 1:S3-S12. DOI: 10.1016/S1386-6532(09)70002-2. View

20.

Wheeler C, Hunt W, Cuzick J, Langsfeld E, Pearse A, Montoya G . A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer. 2012; 132(1):198-207. PMC: 3852415. DOI: 10.1002/ijc.27608. View